RU2016114541A - Способ получения оболочечного вируса - Google Patents

Способ получения оболочечного вируса Download PDF

Info

Publication number
RU2016114541A
RU2016114541A RU2016114541A RU2016114541A RU2016114541A RU 2016114541 A RU2016114541 A RU 2016114541A RU 2016114541 A RU2016114541 A RU 2016114541A RU 2016114541 A RU2016114541 A RU 2016114541A RU 2016114541 A RU2016114541 A RU 2016114541A
Authority
RU
Russia
Prior art keywords
medium
paragraphs
kit
virus
lentivirus
Prior art date
Application number
RU2016114541A
Other languages
English (en)
Russian (ru)
Inventor
Давид ФЕНАР
Original Assignee
Женетон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50424334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016114541(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Женетон filed Critical Женетон
Publication of RU2016114541A publication Critical patent/RU2016114541A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2016114541A 2013-09-16 2014-09-12 Способ получения оболочечного вируса RU2016114541A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1358909A FR3010720B1 (fr) 2013-09-16 2013-09-16 Procede de production de virus enveloppes
FR1358909 2013-09-16
PCT/FR2014/052279 WO2015036713A1 (fr) 2013-09-16 2014-09-12 Procede de production de virus enveloppes

Publications (1)

Publication Number Publication Date
RU2016114541A true RU2016114541A (ru) 2017-10-23

Family

ID=50424334

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016114541A RU2016114541A (ru) 2013-09-16 2014-09-12 Способ получения оболочечного вируса

Country Status (11)

Country Link
US (1) US10125352B2 (enExample)
EP (1) EP3047025B1 (enExample)
JP (1) JP6629210B2 (enExample)
CN (1) CN105722984B (enExample)
CA (1) CA2923554C (enExample)
DK (1) DK3047025T3 (enExample)
ES (1) ES2732154T3 (enExample)
FR (1) FR3010720B1 (enExample)
RU (1) RU2016114541A (enExample)
SG (1) SG11201602017YA (enExample)
WO (1) WO2015036713A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
KR20220047635A (ko) 2019-08-23 2022-04-18 론자 워커스빌 아이엔씨. 렌티바이러스 벡터의 생산을 위한 방법 및 작제물
AU2022212090A1 (en) 2021-01-28 2023-07-06 Allogene Therapeutics, Inc. Methods for transducing immune cells
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5110696B2 (ja) 2004-11-05 2012-12-26 ウェルスタット バイオロジクス コーポレイション 安定かつ濾過可能なエンベロープで覆われたウイルス処方物
ATE539149T1 (de) 2006-04-20 2012-01-15 Wyeth Llc Reinigungsverfahren zur isolierung von gereinigtem vesikulärem stomatitisvirus aus zellkultur
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
JP6175055B2 (ja) * 2011-06-30 2017-08-02 ジェネトン ウイルス感染増強特性を有するペプチドおよびその使用
CN104136605B (zh) * 2011-11-24 2018-08-14 吉尼松公司 与工业制药应用相容的可放大的慢病毒载体生产系统
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes

Also Published As

Publication number Publication date
WO2015036713A1 (fr) 2015-03-19
JP6629210B2 (ja) 2020-01-15
EP3047025A1 (fr) 2016-07-27
US20160230147A1 (en) 2016-08-11
EP3047025B1 (fr) 2019-04-03
DK3047025T3 (da) 2019-06-24
CA2923554A1 (fr) 2015-03-19
CN105722984B (zh) 2021-08-13
SG11201602017YA (en) 2016-04-28
JP2016530890A (ja) 2016-10-06
US10125352B2 (en) 2018-11-13
FR3010720B1 (fr) 2017-08-11
FR3010720A1 (fr) 2015-03-20
CN105722984A (zh) 2016-06-29
CA2923554C (fr) 2019-10-29
ES2732154T3 (es) 2019-11-20

Similar Documents

Publication Publication Date Title
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
BR112023017213A2 (pt) Vetores lentivirais direcionados a linfócitos
PH12019502774A1 (en) ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
NZ607686A (en) Semi-stable production of lentiviral vectors
EP3083970A1 (fr) Procédé de purification de virus ou vecteurs viraux enveloppes
WO2021011936A3 (en) Cell-type selective immunoprotection of cells
FI3497224T3 (fi) Laajamittainen pei-välitteinen plasmiditransfektio
RU2017102986A (ru) Новые люциферазы и способы их использования
Yan et al. Effects of medium composition and genetic background on Agrobacterium-mediated transformation efficiency of Lentinula edodes
JP2016530890A5 (enExample)
Jargalsaikhan et al. The dual-pseudotyped lentiviral vector with VSV-G and Sendai virus HN enhances infection efficiency through the synergistic effect of the envelope proteins
ES2732154T3 (es) Procedimiento de producción de virus envueltos
Yu et al. Effect of phosphorylation sites mutations on the subcellular localization and activity of AGPase Bt2 subunit: Implications for improved starch biosynthesis in maize
Yuan et al. Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti‐Her2 chimeric antigen receptor gene
AU2018261637A1 (en) Improved lentiviruses for transduction of hematopoietic stem cells.
Li et al. Strawberry vein banding virus P6 protein is a translation trans-activator and its activity can be suppressed by FveIF3g
Mattioli et al. Tuning VSV-G Expression Improves Baculovirus Integrity, Stability and Mammalian Cell Transduction Efficiency
WO2008058752A3 (en) Lentiviral vectors for gene transfer in quiescent (g0) cells
Li et al. Cell fate conversion by mRNA
CN104178514A (zh) 一种提高AcMNPV多角体内部外源蛋白含量的方法
CN112342243A (zh) 表达人源sting蛋白的猪源细胞的构建方法和应用
WO2010134975A3 (en) Methods for enhancing infectivity of retroviruses
Elahi et al. Complementary cell lines for protease gene-deleted single-cycle adenovirus vectors
Simonin et al. Early to late VSV-G expression in AcMNPV BV enhances transduction in mammalian cells but does not affect virion yield in insect cells
Cua et al. A Novel Monoclonal Antibody Against a Modified Vaccinia Ankara (MVA) Envelope Protein as a Tool for MVA Virus Titration by Flow Cytometry

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190802